Arca
Skip to content

Gliosarcoma

Drug research and approvals for gliosarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 13 studies of gliosarcoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.

  • Recruiting worldwide: 13
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 13 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

5 in phase 3, 51 in phase 2, 46 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Temozolomide
Phase 3 DNA inhibitor
Bevacizumab
Phase 3 Vascular endothelial growth factor A inhibitor
Lomustine
Phase 3 DNA inhibitor
Rindopepimut
Phase 3 Epidermal growth factor receptor erbB1 vaccine antigen
Depatuxizumab mafodotin
Phase 3 Epidermal growth factor receptor erbB1 binding agent
Erlotinib
Phase 2 Epidermal growth factor receptor erbB1 inhibitor
Temsirolimus
Phase 2 FK506-binding protein 1A inhibitor
Vorinostat
Phase 2 Histone deacetylase 1 inhibitor
Hydroxyurea
Phase 2 Ribonucleoside-diphosphate reductase RR1 inhibitor
Irinotecan
Phase 2 DNA topoisomerase I inhibitor
Sorafenib
Phase 2 Serine/threonine-protein kinase RAF inhibitor
Carmustine
Phase 2 Glutathione reductase inhibitor
Pembrolizumab
Phase 2 Programmed cell death protein 1 inhibitor
Nivolumab
Phase 2 Programmed cell death protein 1 inhibitor
Cediranib
Phase 2 Stem cell growth factor receptor inhibitor
Tipifarnib
Phase 2 Protein farnesyltransferase inhibitor
Cilengitide
Phase 2 Integrin alpha-V/beta-3 antagonist
Topotecan
Phase 2 DNA topoisomerase I inhibitor
Vandetanib
Phase 2 Tyrosine-protein kinase SRC inhibitor
Ipilimumab
Phase 2 Cytotoxic T-lymphocyte protein 4 inhibitor
Bortezomib
Phase 2 26S proteasome inhibitor
Cyclophosphamide anhydrous
Phase 2 DNA inhibitor
Guanine
Phase 2
Carboplatin
Phase 2 DNA inhibitor
Pazopanib
Phase 2 Macrophage colony stimulating factor receptor inhibitor
Aflibercept
Phase 2 Vascular endothelial growth factor A inhibitor
Gefitinib
Phase 2 Epidermal growth factor receptor erbB1 inhibitor
Dasatinib anhydrous
Phase 2 Tyrosine-protein kinase ABL inhibitor
Imatinib
Phase 2 Tyrosine-protein kinase ABL inhibitor
Filgrastim
Phase 2 Granulocyte colony stimulating factor receptor agonist

Showing the 30 furthest along of 102 in trials.

How Its Trials Ended

236 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 88 whose ending is known, 15% met their primary endpoint, 24% missed it and 61% stopped early.

  • Completed, result not reported10344%
  • Ongoing4017%
  • Missed its primary endpoint219%
  • Stopped: other or unclear208%
  • Met its primary endpoint136%
  • Stopped: enrollment or feasibility136%
  • Stopped: sponsor or business decision115%
  • Status unknown52%
  • Stopped: lack of efficacy42%
  • Stopped: funding42%
  • Stopped: safety21%

Trials Authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Aug 8, 2016A phase II, multi-center, open-label study of a conditionally replicative adenovirus (dnx-2401) with pembrolizumab (keytruda) for recurrent glioblastoma or…DNX-2401 / keytrudaDnatrix, IncOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.